Search Results - "Smyth, Mark J."

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance by Zitvogel, Laurence, Galluzzi, Lorenzo, Smyth, Mark J., Kroemer, Guido

“…Conventional chemotherapeutics and targeted antineoplastic agents have been developed based on the simplistic notion that cancer constitutes a cell-autonomous…”
Get full text

Balancing natural killer cell activation through paired receptors by Martinet, Ludovic, Smyth, Mark J.

“…Key Points A family of molecules, including CD226, T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and CD96, that bind nectin and…”
Get full text

Targeting natural killer cells in cancer immunotherapy by Guillerey, Camille, Huntington, Nicholas D, Smyth, Mark J

“…There is now a major effort to fully exploit the anti-tumor properties of NK cells in the clinic. In this Review, Smyth and colleagues detail recent advances…”
Get full text

Cancer immunoediting and immune dysregulation in multiple myeloma by Nakamura, Kyohei, Smyth, Mark J., Martinet, Ludovic

“…Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant advances have been made in understanding immune dysfunction and…”
Get full text

Targeting cancer‐related inflammation in the era of immunotherapy by Nakamura, Kyohei, Smyth, Mark J

“…Recent advances in cancer immunotherapy, particularly immune checkpoint blockade therapy have dramatically changed the therapeutic strategy against advanced…”
Get full text

The pre-metastatic niche: finding common ground by Sceneay, Jaclyn, Smyth, Mark J., Möller, Andreas

“…It is rapidly becoming evident that the formation of tumor-promoting pre-metastatic niches in secondary organs adds a previously unrecognized degree of…”
Get full text

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion by Schreiber, Robert D., Old, Lloyd J., Smyth, Mark J.

“…Understanding how the immune system affects cancer development and progression has been one of the most challenging questions in immunology. Research over the…”
Get full text

Clinical relevance of host immunity in breast cancer: from TILs to the clinic by Savas, Peter, Salgado, Roberto, Denkert, Carsten, Sotiriou, Christos, Darcy, Phillip K., Smyth, Mark J., Loi, Sherene

“…Key Points The detection of tumour-infiltrating lymphocytes (TILs) on routine histology constitutes a robust prognostic and predictive biomarker in patients…”
Get full text

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy by Dougall, William C., Kurtulus, Sema, Smyth, Mark J., Anderson, Ana C.

“…Summary While therapies targeting the co‐inhibitory or immune checkpoint receptors PD‐1 and CTLA‐4 have shown remarkable success in many cancers, not all…”
Get full text

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs by ALLARD, Bertrand, POMMEY, Sandra, SMYTH, Mark J, STAGG, John

“…Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been associated with durable clinical…”
Get full text

Targeting immune checkpoints in hematological malignancies by Salik, Basit, Smyth, Mark J, Nakamura, Kyohei

“…Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have…”
Get full text

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses by Young, Arabella, Ngiow, Shin Foong, Barkauskas, Deborah S., Sult, Erin, Hay, Carl, Blake, Stephen J., Huang, Qihui, Liu, Jing, Takeda, Kazuyoshi, Teng, Michele W.L., Sachsenmeier, Kris, Smyth, Mark J.

“…Preclinical studies targeting the adenosinergic pathway have gained much attention for their clinical potential in overcoming tumor-induced immunosuppression…”
Get full text

BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies by Ambalathingal, George R, Francis, Ross S, Smyth, Mark J, Smith, Corey, Khanna, Rajiv

“…BK polyomavirus (BKV) causes frequent infections during childhood and establishes persistent infections within renal tubular cells and the uroepithelium, with…”
Get full text

Resistance to PD1/PDL1 checkpoint inhibition by O’Donnell, Jake S, Long, Georgina V, Scolyer, Richard A, W. L. Teng, Michele, Smyth, Mark J

“…Highlights • Resistance to anti-PD1 therapy affects up to ∼70% of patients treated. • Resistance can be primary or acquired. • Tumor intrinsic mechanisms that…”
Get full text

Targeting cancer-derived adenosine: new therapeutic approaches by Young, Arabella, Mittal, Deepak, Stagg, John, Smyth, Mark J

“…CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor…”
Get more information

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases by Teng, Michele W L, Bowman, Edward P, McElwee, Joshua J, Smyth, Mark J, Casanova, Jean-Laurent, Cooper, Andrea M, Cua, Daniel J

“…Cua and colleagues discuss the cellular and molecular rationale for targeting IL-12 and IL-23 for therapeutic purposes in inflammatory diseases; they also…”
Get full text

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment by O'Donnell, Jake S, Hoefsmit, Esmée P, Smyth, Mark J, Blank, Christian U, Teng, Michele W L

“…Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated durable efficacy in a proportion of patients with advanced/metastatic…”
Get full text

The TRAIL apoptotic pathway in cancer onset, progression and therapy by Johnstone, Ricky W, Smyth, Mark J, Frew, Ailsa J

“…Key Points Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent stimulator of apoptosis, and tumour cells are significantly more…”
Get full text

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells by Ma, Yuting, Adjemian, Sandy, Mattarollo, Stephen R., Yamazaki, Takahiro, Aymeric, Laetitia, Yang, Heng, Portela Catani, João Paulo, Hannani, Dalil, Duret, Helene, Steegh, Kim, Martins, Isabelle, Schlemmer, Frederic, Michaud, Mickaël, Kepp, Oliver, Sukkurwala, Abdul Qader, Menger, Laurie, Vacchelli, Erika, Droin, Nathalie, Galluzzi, Lorenzo, Krzysiek, Roman, Gordon, Siamon, Taylor, Philip R., Van Endert, Peter, Solary, Eric, Smyth, Mark J., Zitvogel, Laurence, Kroemer, Guido

“…The therapeutic efficacy of anthracyclines relies on antitumor immune responses elicited by dying cancer cells. How chemotherapy-induced cell death leads to…”
Get full text

Natural innate and adaptive immunity to cancer by Vesely, Matthew D, Kershaw, Michael H, Schreiber, Robert D, Smyth, Mark J

“…The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against…”
Get full text